A Single-Dose, Open-Label, Prospective Clinical Study of Denosumab in Patients with Primary Hyperparathyroidism

2014 ◽  
Vol 10 (3) ◽  
pp. 396-403
Author(s):  
D Grigorie
Keyword(s):  
Single Dose ◽  
Clinical Study ◽  
Primary Hyperparathyroidism ◽  
Prospective Clinical Study ◽  
Open Label

scholarly journals An open label single arm prospective clinical study on Vatagajankusharasa with Pippali Churna and Manjishta Kwatha as Anupana in Viswachi (cervical spondylosis)

2020 ◽  
Vol 5 (01) ◽  
pp. 73-80
Author(s):  
Moh Gulfam ◽  
Totad Muttappa ◽  
Neelam Bisht ◽  
Vishnu M L ◽  
Yadu Gopan
Keyword(s):  
Clinical Study ◽  
Ordinal Data ◽  
Cervical Spondylosis ◽  
Signs And Symptoms ◽  
Upper Extremities ◽  
Secondary Outcome ◽  
Prospective Clinical Study ◽  
Rank Tests ◽  
Open Label ◽  
Signed Rank

Background: Viswachi is one among the 80 Nanatmaja Vata Vyadhi. This disease affects the neck and upper extremities with the signs and symptoms like Ruk, Stambha, Toda, Bahu Karmakshaya. Vatagajankusha Rasa is a combination of Vyosha, Bhasmas, Vatsanabha, Karkatasringi, Haritaki etc. It has Vatakaphahara, Vikasi, Vyavayi, Rasayana etc. properties. It is said to be effective in treating Visawachi in 7 days if given along with Pippali Churna and Manjishta Kwatha. Aims and Objectives: To evaluate the efficacy of Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana in the management of Viswachi (Cervical spondylosis). Methodology: Among 35 registered patients, 30 completed the course of treatment. They were administered with Vatagajankusha Rasa 1 tablet (125 mg) after food with Anupana 3gm Pippali Churna and 15 ml Manjishta Kwatha twice daily (morning and evening) for a period of 7 days. Nominal and ordinal data were analysed using non parametric tests like McNemar and Wilcoxon’s signed rank tests respectively. Result: Assessment parameters like Ruk, Toda, Sthambha and Bahukarma Kshya. There was statistically significant improvement in the primary and secondary outcome measures (p less than 0.05 was observed). Conclusion: Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana is effective in the management of Viswachi (Cervical spondylosis).

scholarly journals Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study

2020 ◽  
Author(s):  
Jeffrey D Klausner ◽  
Claire C Bristow ◽  
Olusegun O Soge ◽  
Akbar Shahkolahi ◽  
Toni Waymer ◽  
...  
Keyword(s):  
Single Dose ◽  
Clinical Study ◽  
Scale Up ◽  
Treatment Strategies ◽  
Prospective Clinical Study ◽  
Dose Oral ◽  
Novel Treatment Strategies ◽  
Oral Ciprofloxacin ◽  
Culture Positive

Abstract Background Novel treatment strategies to slow the continued emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae are urgently needed. A molecular assay that predicts in vitro ciprofloxacin susceptibility is now available but has not been systematically studied in human infections. Methods Using a genotypic polymerase chain reaction assay to determine the status of the N. gonorrhoeae gyrase subunit A serine 91 codon, we conducted a multisite prospective clinical study of the efficacy of a single oral dose of ciprofloxacin 500 mg in patients with culture-positive gonorrhea. Follow-up specimens for culture were collected to determine microbiological cure 5–10 days post-treatment. Results Of the 106 subjects possessing culture-positive infections with wild-type gyrA serine N. gonorrhoeae genotype, the efficacy of single-dose oral ciprofloxacin treatment in the per-protocol population was 100% (95% 1-sided confidence interval, 97.5–100%). Conclusions Resistance-guided treatment of N. gonorrhoeae infections with single-dose oral ciprofloxacin was highly efficacious. The widespread introduction and scale-up of gyrA serine 91 genotyping in N. gonorrhoeae infections could have substantial medical and public health benefits in settings where the majority of gonococcal infections are ciprofloxacin susceptible. Clinical Trials Registration NCT02961751.

scholarly journals Redefining face contour with a novel anti-aging cosmetic product: an open-label, prospective clinical study

2017 ◽  
Vol Volume 10 ◽  
pp. 473-482 ◽  
Author(s):  
Aurora Garre ◽  
Gemma Martinez-Masana ◽  
Jaime Piquero-Casals ◽  
Corinne Granger
Keyword(s):  
Clinical Study ◽  
Prospective Clinical Study ◽  
Open Label ◽  
Cosmetic Product ◽  
Face Contour
Sign in / Sign up

Export Citation Format

Share Document